Merck Sharpe & Dohme (MSD) – Major Upgrade to Pharmaceutical Reactor Bay & Hydrogenator Suite

Background

MSD is the UK subsidiary of Merck & Co. Inc., a leading healthcare company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.

Requirement

MSD required HFL to carry out the design, procurement, installation, commissioning and re-validation of a major upgrade to a pharmaceutical reactor bay and Hydrogenator suite at their Hoddesdon site.

Response

HFL was able to provide the required support which included:

• Process – Specification of equipment and process modification work
• Civil/Structural – Design of modified structures and fire walls
• Mechanical/Piping – Procurement, expediting and inspection of all equipment, generation of
• scope of work packages and production of ‘Issued for Construction’ drawing packages
• Control – Modification of existing Delta V system
• Electrical/Instrumentation – Specification of instruments, generation of scope work packages and production of ‘Issued for Construction’ drawing packages
• Construction – All project preparation work, installation and commissioning supervised by an on site supervisor
• Commissioning/Validation – Project fully commissioned, re-validated and handed over to the client

Result

The major upgrade provided MSD with a fully operating Reactor Bay and Hydrogenator Suite which has allowed it to significantly increase production capacity and considerably reduce batch times.